Article

Multiple routes of administration viable for endophthalmitis prophylaxis

San Francisco-Although the debate continues regarding the pros and cons of different approaches to antibiotic prophylaxis for postoperative endophthalmitis, available data are clear in demonstrating that it is critical to assure an effective concentration is present at the time of surgery and maintained in the early postoperative period, said Randall J. Olson, MD, John A. Moran Presidential Professor and chairman of the Department of Ophthalmology and Visual Sciences, University of Utah School of Medicine, Salt Lake City.

San Francisco-Although the debate continues regarding the pros and cons of different approaches to antibiotic prophylaxis for postoperative endophthalmitis, available data are clear in demonstrating that it is critical to assure an effective concentration is present at the time of surgery and maintained in the early postoperative period, said Randall J. Olson, MD, John A. Moran Presidential Professor and chairman of the Department of Ophthalmology and Visual Sciences, University of Utah School of Medicine, Salt Lake City.

Reviewing the literature on this topic, Dr. Olson said that although intracameral cefuroxime is the only prophylactic regimen that has been demonstrated effective in a prospective, randomized controlled study, reasonably good evidence also exists supporting the conclusion that antibiotics administered topically or even by subconjunctival injection are effective for decreasing endophthalmitis risk.

Published results from analyses of data collected at the John Moran Eye Center, University of Utah School of Medicine, showed that in a regimen including frequent use of topical fourth-generation fluoroquinolones on the day of surgery, the incidence of endophthalmitis was about 0.06%.

"However, in a multivariate analysis, we found a 14-fold increased incidence if the antibiotic was started on the day after surgery," he said. "Keep in mind, however, that we are also very careful to suture any incision where the integrity is questionable."

Looking ahead, Dr. Olson said he anticipates that intracameral antibiotic use will become standard, but only with the availability of a commercially available unit-dose preparation. Which antibiotic will be marketed in this manner remains to be seen, but it will need to address concerns relating to emerging microbial resistance, and surgeons should expect that intracameral injection will not be a stand-alone technique but rather used in combination with topical treatment, he concluded.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) From MIGS to gene therapy: Inder Paul Singh, MD, celebrates the past and future of glaucoma care
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
© 2025 MJH Life Sciences

All rights reserved.